Effectiveness of quality incentive payments in general practice (EQuIP-GP): a study protocol for a cluster-randomised trial of an outcomes-based funding model in Australian general practice to improve patient care by Peterson, Gregory M et al.
Bond University
Research Repository
Effectiveness of quality incentive payments in general practice (EQuIP-GP)
Peterson, Gregory M; Russell, Grant; Radford, Jan C; Zwar, Nick; Mazza, Danielle;
Eckermann, Simon; Mullan, Judy; Batterham, Marijka J; Hammond, Athena; Bonney, Andrew
Published in:
BMC Health Services Research
DOI:
10.1186/s12913-019-4336-2
Published: 29/07/2019
Document Version:
Publisher's PDF, also known as Version of record
Link to publication in Bond University research repository.
Recommended citation(APA):
Peterson, G. M., Russell, G., Radford, J. C., Zwar, N., Mazza, D., Eckermann, S., ... Bonney, A. (2019).
Effectiveness of quality incentive payments in general practice (EQuIP-GP): a study protocol for a cluster-
randomised trial of an outcomes-based funding model in Australian general practice to improve patient care.
BMC Health Services Research, 19(1), [529]. https://doi.org/10.1186/s12913-019-4336-2
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 06 Nov 2019
STUDY PROTOCOL Open Access
Effectiveness of quality incentive payments
in general practice (EQuIP-GP): a study
protocol for a cluster-randomised trial of an
outcomes-based funding model in
Australian general practice to improve
patient care
Gregory M. Peterson1, Grant Russell2, Jan C. Radford1, Nick Zwar3, Danielle Mazza2, Simon Eckermann4,
Judy Mullan5, Marijka J. Batterham6, Athena Hammond7 and Andrew Bonney5*
Abstract
Background: There is international interest in whether improved primary care, in particular for patients with
chronic or complex conditions, can lead to decreased use of health resources and whether financial incentives help
achieve this goal. This trial (EQuIP-GP) will investigate whether a funding model based upon targeted, continuous
quality incentive payments for Australian general practices increases relational continuity of care, and lessens
health-service utilisation, for high-risk patients and children.
Methods: We will use a mixed methods approach incorporating a two-arm pragmatic cluster randomised control
trial with nested qualitative case studies. We aim to recruit 36 general practices from Practice-Based Research
Networks (PBRN) covering urban and regional areas of Australia, randomised into intervention and control groups.
Control practices will provide usual care while intervention practices will be supported to implement a new service
model incorporating incentives for relational continuity and timely access to appointments. Patients will comprise
three groups: older (over 65 years); 18–65 years with chronic and/or complex conditions; and those aged less than
16 years with increased risk of hospitalisation. The funding model includes financial incentives to general
practitioners (GPs) for providing longer consultations, same day access and timely follow-up after hospitalisation to
enrolled patients. The payments are proportional to expected health system savings associated with improved
quality of GP care. An outreach facilitator will work with practices to help incorporate the incentive model into
usual work. The main outcome measure is relational continuity of care (Primary Care Assessment Tool short-form
survey), with secondary outcomes including health-related quality of life and health service use (hospitalisations,
emergency presentations, GP and specialist services in the community, medicine prescriptions and targeted
pathology and imaging ordering). Outcomes will be initially evaluated over a period of 12 months, with ongoing
data collection for 5 years.
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Discussion: The trial will provide robust evidence on a novel approach to providing continuous incentives for
improving quality of general practice care, which can be compared to block payment incentives awarded at target
quality levels of pay-for-performance, both within Australia and also internationally.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12618000105246. Registered on 23 January 2018.
Keywords: Primary care, General practice, Quality, Continuity of care, Funding, Incentivisation, Health service utilisation
Background
It is clear that health care systems with strong primary
care have better population health [1], lower rates of
unnecessary hospitalisations and more equitable health
outcomes [2]. Key components of primary care that con-
tribute to improved population health outcomes include
providing affordable first access to the health system for all
medical needs; person-(not disease) focused care over time;
comprehensiveness of care; and coordination of care [1, 3].
At the same time it has become clear that primary care fee-
for-service health payment systems, as in Australia, need
fundamental reform to create incentives better aligned to
quality of care, rather than encouraging high-volume short
consultations with resulting downstream health and health
system impacts in populations over time [4].
International evidence has highlighted the significant
benefits that relational continuity (an ongoing therapeutic
relationship with one or more providers [5]) has for quality
and outcomes of primary care, including decreasing
hospitalisations for Ambulatory Care-Sensitive Conditions
(ACSCs) and reducing mortality risk [6–8]. There is also
evidence that access to longer consultations has a range of
benefits in terms of the GP-patient relationship and in the
quality of assessment, dealing with complexity, care
planning and preventive care [9–14]. However, under the
current fee-for-service system for GPs in Australia, rebates
under the Medicare Benefits Schedule (MBS), subsidised by
the Federal Government, are proportionally less for time
spent conducting longer encounters than shorter encoun-
ters. This feature incentivises rapid patient turnover and
has the potential to contribute to lower quality of care,
particularly for patients living with chronic disease [15, 16].
Consequently, with financial assistance from the Federal
Government, the Royal Australian College of General
Practitioners (RACGP) sought proposals to develop and
trial alternative funding models to support high-quality
primary care. This trial formed the basis of one of the
funded proposals.
Objectives
The study aims to evaluate the impact of a new funding
model in primary care, comprising targeted incentives for
enrolment with a preferred provider, longer consultations,
same day access and structured follow-up after hospitalisa-
tion, on the quality of care and health service utilisation,
and related costs for patients at increased risk of hospital-
isation. The impact of the intervention will be compared to
usual care.
The funding model trial will test incentives for specific
quality improvement factors in high-risk chronic disease
populations and provides payment incentives that are
proportional to the expected health system cost savings
resulting from those patients’ care improvement. This
model enables incentives for continuous quality of care
improvement within existing overall health system budgets,
rather than previous quality incentive models with fixed
block payments at target thresholds having localised incen-
tives and without budgetary justification [17–19].
The primary hypothesis is that among high-risk patients
and children attending general practices, the introduction
of a practice-level service model incorporating continuous
and graded quality improvement incentives, will improve
patient-perceived relational continuity. Our specific re-
search questions are:
 In patients over the age of 65 living with chronic
illness, what is the impact of an incentivised
practice-level service model promoting access to
preferred primary care providers, longer
consultations and structured post-hospitalisation
follow-up on:
a. patient-perceived relational continuity of care;
b. referrals for specified radiology and pathology
services;
c. medicine prescriptions;
d. potentially avoidable hospitalisations (PAHs); and
e. emergency department attendances.
 Does the application of this model in patients under
16 years of age (with defined comorbidities) provide
improved access to same day care?
 Is the model cost-effective when used in each
population?
 How acceptable is the model for patients and staff
members of primary care practices?
Methods/design
Overview
A mixed methods approach, incorporating a two-arm
pragmatic cluster randomised controlled trial (RCT)
with nested qualitative case studies, will be used to
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investigate the effectiveness, acceptability, resource use
and costs of the service model in general practice. Prag-
matic RCTs have emerged as a way of bridging the gap be-
tween traditional RCTs, which have a good internal
validity, and observational studies, which have good exter-
nal validity [20]. Pragmatic trials measure effectiveness
and seek to maximise external validity to ensure that the
results can be generalised [21]. To decrease contamination
bias we will use cluster randomisation at the general prac-
tice level, where practices (and their associated physi-
cians), rather than the individual patients, are randomised
to the intervention or usual care arm funding models [21].
Our theoretical framework for the study is informed
by the literature on organisational change, where organi-
sations are considered as a whole, rather than as a set of
independent attributes [22–25], and methods for struc-
turing continuous quality of care improvement incen-
tives [17–19]. Three principles underpin the work.
 Use of the United Kingdom Medical Research
Council framework for designing complex
interventions, where previous data from baseline
qualitative and observational work will be
incorporated into the design and evaluation of a
trial of a complex intervention [26].
 Implementation based on intervention facilitation
in primary care, where skilled individuals work to
identify and overcome challenges in implementing
evidence-based care and inefficiencies in non-clinical
routines and processes [27].
 A realist approach to the process evaluation of the
intervention [28], seeking to identify “what worked
for whom, in what context, when and why” [29].
Quality improvement research has been criticised
for not capturing a sufficient understanding of the or-
ganisational change process about why interventions
do or do not work [23]. Therefore, this study is also
incorporating qualitative case studies to investigate
barriers and enablers of the service model within the
intervention general practices.
The qualitative component of the research will pro-
vide insights into the impacts of the intervention on
patients and general practice staff; develop an under-
standing of how the intervention is experienced by
participants and assess its acceptability from multiple
perspectives; explore and describe the contexts, mech-
anisms and outcomes that influence uptake and im-
plementation of the intervention; and investigate the
attitudes and beliefs of patients and general practice
staff about the use of financial incentives in the gen-
eral practice setting.
Setting
The study will be set in 36 general practices across three
practice-based research networks (PBRNs) in NSW,
Victoria and Tasmania (Table 1). The study’s three col-
laborating centres enable coverage and generalisability to
practices across regional, rural and urban settings.
Practice inclusion criteria
Practices will:
 be delivering generalist (i.e. non-specialised) primary
care medical services and employing at least one
full-time equivalent GP;
 have been in business for at least 1 year and not be
intending to close for a further 2 years.
 be able to generate patient encounter data through
either of the two most commonly used general
practice clinical software systems in Australia
(Medical Director or Best Practice);
 consent to the use of NPS MedicineWise
MedicineInsight clinical data extraction software
[30]; and
 not be registered as participants or potential
participants in the Australian Government Health
Care Homes trial [31].
Practice recruitment
Recruitment will commence through the three collaborating
PBRNs. Publicity will be developed with the relevant media
Table 1 Details of the study’s three collaborating practice-based research networks (PBRNs)
Name of Practice Based Research
Network
The Northern Tasmanian Practice Based
Research Network
Monash Practice Based
Research Network (MONReN)
The Illawarra and Southern Practice
Research Network (ISPRN)
Region Northern Tasmania South-East Melbourne South-East New South Wales
Affiliated organisations University of Tasmania Monash University University of Wollongong
Regional population Northern Tasmania Inner East Melbourne,
Bayside, South Eastern,
Eastern and Frankston and
Mornington Peninsula
regions of Melbourne
Illawarra, Shoalhaven, Southern
NSW, Murrumbidgee, Bega
Number of practices in region 28 479 185
Potential PBRN eligible practices 13 290 40
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units at each site and communicated through the PBRN
newsletter and/or blog posts. Publicity announcements
will contain contact details for the research team,
allowing eligible practices to contact the team directly
at this point. A week after publicity appears, all eligible
practices in the PBRN will be sent a letter, a compre-
hensive information pack and consent form. The re-
search team will contact non-responding practices by
phone 1 week after the information mail-out. Practices
expressing interest in participation will receive a visit from
investigators or a research team member to facilitate a
more detailed discussion of the study. The general prac-
tice recruitment approach is outlined in Fig. 1.
Practitioner and support staff recruitment
Once practices have consented we will seek to iden-
tify individual general practitioners (GPs) and general
practice registrars (trainees)(GPRs) under supervision,
along with practice nurses (PNs) and practice man-
ager (PMs), to participate. To reflect current work
practices, GPs/GPRs with full-time or part-time work
patterns will be included. GPs are not eligible if they
provide a limited scope of practice (e.g. only skin
cancer surgery). As part of the recruitment process,
GPs, PNs and PMs who agree to participate will sign
the consent forms.
Patient inclusion criteria
Three groups of ‘high-risk’ patients will be included in
the study:
 aged over 65 years;
 aged 18–65 years with common chronic and/or
complex ACSC (chronic obstructive pulmonary
disease (COPD), diabetes, angina (or ischaemic heart
disease), cardiac failure, asthma); or
Fig. 1 General practice recruitment approach
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 aged less than 16 years and at risk of
hospitalisation, defined by previous diagnosis
with a high-risk condition (e.g. asthma, epilepsy,
dental condition, acute bronchiolitis, pneumonia
or croup).
Patient recruit1ment
Following practice randomisation, in both intervention and
control practices, an electronic database search will be con-
ducted by the PN, PM or appropriate administrative staff
member (assisted by a research team member, when
necessary) using the practice’s own clinical software search
facility to identify active patients (attended the practice
three or more times in the last 2 years) who meet the inclu-
sion criteria for the study.
Practices will generate lists of eligible patients seen by
participating GPs, using 31st May 2018 as an index
consultation day from which to extend searches. The
generated lists will be screened by patients’ GPs to ex-
clude patients unable to understand English or with sig-
nificant cognitive impairment or distress. Then, the
practice will post out a supplied information pack,
consisting of a letter of invitation, an information sheet
and a consent form, to a total of 200 eligible patients.
This process will be the same in both the intervention
and control groups. Information packs will be distrib-
uted to a sample of three patient cohorts from each
practice, as follows:
 n = 60 patients aged over 65 years;
 n = 60 patients aged 18–65 years with chronic and/
or complex ACSCs; and
 n = 80 parents of eligible children aged less than 16
years.
From the 200 information packs it is anticipated
that, via an expected response rate of 25%, we can
meet the target recruitment of 50 patients per prac-
tice. If recruitment is less than anticipated, a further
wave of invitations will be sent and/or GPs can dir-
ect eligible patients to the trial information packs in
each surgery. Patients’ consent to participate will be
interpreted as the return of a completed consent
form to the practice/the research team.
Randomisation of practices
We will use randomisation by minimisation to reduce the
risk of the trial being unbalanced across arms by practice
size (less than or equal to 5 full-time equivalent GPs, or 6 or
more) and Index of Relative Socioeconomic Disadvantage
(IRSD) at each practice’s local government area (whether in
the most disadvantaged 40% or not, using Socio-Economic
Indexes for Areas (SEIFA) [32]. Randomisation will be
dynamic and conducted by the trial statistician (MJB) as
practice level consent is obtained. The identity of the
practices will be masked from the statistician until after the
analyses are performed. The project officers in each state
will enter a code for each consented practice into a cloud-
based database in the order that the practice consents are
received and notify the statistician by email. The statistician
will then perform dynamic randomisation by minimisation,
balancing for practice size and IRSD, entering the allocation
into the database. With the exception of the statistician, all
participants and project staff will be aware of the practice
allocation to the control or intervention arms of the trial.
Intervention
Intervention general practices will be supported to imple-
ment a new service model incorporating quality incentives
for patients’ relational continuity and timely access. The
intervention itself will comprise a mechanism of, firstly,
patient enrolment within a practice. The practice will then
offer enrolled patients: a) guaranteed access to a minimum
of three longer appointment types over the study period
for older patients or those with chronic or complex
illness; b) a review visit within 7 days of admission to an
emergency department or hospital, or after other signifi-
cant health events; and c) for patients aged less than 16
years, same day access for acute conditions.
Figure 2 summarises the incentive structure. All
incentives are calculated over the 12 months of the trial
and compared with the 12-month period immediately
previous to the trial. The incentive payments apply to
the percentage of change achieved across the group of
enrolled patients at the level of the practice. The incen-
tives supplement the existing payment arrangements.
All incentives will be calculated and paid at the conclu-
sion of the 12-month trial.
An intervention facilitator (IF) will be employed by
each of the three collaborating centres. They will work
with practices in the intervention arm of the study to
facilitate implementation of the new service model.
They will also collect data relevant to their facilitator
role using structured diary keeping. These diaries will
contribute data concerning practice culture, commu-
nication and routines, plus information about the
challenges and successes of the intervention. The
EQuIP-GP Trial timeline is summarised in Table 2.
Standard care
Control practices will provide usual care. Usual care in
the context of this study is care received by patients in
daily practice in regard to their particular health con-
cerns [21], and represents normal practice against which
to compare the intervention.
Both intervention and control practices will be
provided access to links to quality improvement educa-
tion materials (e.g. including Choosing Wisely Australia
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recommendations for improving the quality of health-
care by eliminating unnecessary and sometimes harmful
tests, treatments, and procedures [33]).
Discontinuation criteria
General practices and individual patients can withdraw
at any time, without reason. There are no specific dis-
continuation criteria. Practices and patients can request
withdrawal of their data if they discontinue up until the
time of analyses. Unless requested by the participant,
data will be retained for all participants including with-
drawals and deviations from the protocol.
Outcomes
The primary outcome of the trial is relational continuity,
as measured in the appropriate scale of the 43-item
shortened Primary Care Assessment Tool (PCAT) [34].
The domains of accessibility, coordination and compre-
hensive care in participants will also be measured using
the relevant domain scales of the PCAT [34].
We will assess the use of care-related services in
the 12 months prior to the trial in comparison with
the 12-month trial period. Data elements include:
 total prescription counts per patient and
Pharmaceutical Benefits Scheme (PBS) costs;
 selected pathology services (microscopy, culture and
sensitivity testing for leg ulcer swabs or urine, full
blood count, erythrocyte sedimentation rate, thyroid
function tests, prostate specific antigen and serum
vitamin D level) per patient and Medical Benefits
Schedule (MBS) costs;
 selected radiology services (lower back and chest x-
rays, carotid duplex studies, computed tomography
of the head) per patient and MBS costs; and
 total specialist referrals per patient and MBS costs.
We will also assess and collect data on hospitalisation
and emergency department attendance rates in the 12
months prior to the trial in comparison with the 12-
month trial period and for 5 years following the trial. Due
to funding and time constraints, it is not possible to ad-
equately power the trial to measure a reduction in PAHs
within the study period. Therefore, the study investigators
will establish linked data collection procedures to enable
ongoing data collection and analysis for up to 5 years. Pa-
tient mortality rates will also be assessed for up to 5 years.
The proportion of patients seen within 1 week of
discharge from hospital, and under 16-year-olds seen
on the same day as requested for acute conditions,
will be assessed using quarterly manual chart audits
of enrolled patients in each practice performed by
the PNs. In addition, patient/parent perceived ease
of access will be measured by a brief survey at the
beginning and conclusion of the trial, along with
health-related quality of life (EQ-5D-5 L) [35].
Table 3 outlines the EQuIP-GP data variables, and
Fig. 3 the program logic for the trial.
Fig. 2 Plain language incentive structure (as provided to
participating general practices)
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Qualitative substudy
The aim of the qualitative component is to provide con-
text and insight into the experience, acceptability and
success of the intervention from the perspective of
patients, GPs and PMs. A case study methodology
will be used. It is recommended in health research
when studying complex phenomena and the context
in which they are embedded [36]. The methodology
is useful for conducting evaluations and developing
interventions, both of which are relevant for this
study. The constructivist underpinnings of case study
methodology privilege the existence of multiple per-
spectives and subjective meanings [37], making it
ideal to investigate the experiences of different staff
members and patients within the same practice.
Here, the ‘case’ to be examined at each practice is
the uptake and implementation of an intervention
using financial incentives.
The qualitative component combines interviews
and the IF’s diary records. Semi-structured inter-
views will be conducted over the telephone or may
be conducted in person if requested and where logis-
tically viable. A total of 60 interviews (24 with pa-
tients, 24 with GPs and 12 with PMs) will be
conducted – 30 at baseline and 30 at the conclusion
of the 12-month trial. These will be divided evenly
across the three collaborating PBRNs and conducted
in intervention practices only. The case study sites
will be purposively sampled using SEIFA code and
practice size as descriptors to ensure diversity. A
Table 2 EQuIP-GP Trial timeline
Task Name Start Finish
Practice Recruitment April 1 2018 November 30 2018
○ Publicity will be communicated through the PBRN newsletter and/or blog posts
○ After publicity appears, all practices in the three PBRN’s will be sent a letter,
information sheet and consent form.
○ Practices expressing interest will receive a visit from investigators or a research
staff team member to facilitate a more detailed discussion of the study.
Practice Randomisation
○ Dynamic randomisation of practices will occur after consent has been gained by practices.
Data collection
○ Distribution of pre-trial provider and facility surveys to practices
○ A sample of consenting practice staff will be contacted directly by the research team
to arrange qualitative interviews following randomisation
Patient Recruitment June 1 2018 December 31 2018
○ A Practice Nurse in the consenting practices will run an electronic search of the
patient database in order to identify potential participants who meet the inclusion criteria
○ A sample of 200 patients identified in the electronic search will be sent an information
pack containing a letter of invitation, an information sheet and a consent form.
○ After 2 weeks, if recruitment is insufficient, then direct invitation to patients presenting
to the practice will commence
Baseline data collection
○ Distribution of pre-trial patient surveys: PCAT, EQ-5D-5 L HRQOL and ease of access
survey to parents/guardians of <16 patients.
○ A sample of consenting patients will be contacted directly by the research team to
arrange qualitative interviews following recruitment.
Intervention period August 1 2018 July 31 2019
Intervention facilitation
○ Intervention facilitators to visit intervention GP practices 3 times August 1 2018 January 31 2019
Follow-up data collection July 1 2019 August 31 2019
○ A sample of consenting practice staff will be contacted directly by the research
team to arrange follow-up qualitative interviews.
○ Distribution of post-trial patient surveys: PCAT, EQ-5D-5 L and ease of access
survey to parents/guardians of <16 patients.
○ A sample of consenting patients will be contacted directly by the research
team to arrange qualitative interviews.
○ Intervention facilitator interviews
○ Electronic Health Record data extraction for period August 1 2017 – July 31 2019
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Table 3 EQuIP-GP data variables
Data level Variable Dependent (DV) or
independent variable (IV)
Source
Practice Locality IRSD IV Australian Bureau of Statistics [28]
Practice size - 6 or more GP FTEs IV Practice
CIHI Practice surveya IV Practice
GP CIHI Provider surveyb IV GP
Patient EQ-5D-5 L baselinec IV Patient self-completion
EQ-5D-5 L trial completionc DV Patient self-completion
PCAT baseline (primary outcome measure) IV Patient self-completion [29]
PCAT trial completion (primary outcome measure) DV Patient self-completion [29]
Hospitalisations previous 12 months
(emergency department [ED] + admission)
IV Patient self-completion
Hospitalisations during the trial (ED + admission) DV Patient self-completion
Same day consultations <16 years previous 12 months IV Patient self-completion
Same day consultations <16 years during the trial DV Patient self-completion
1 week post-hospital consultations previous 12months IV Patient self-completion
1 week post-hospital consultations during the trial DV Patient self-completion
DOB IV Electronic health record (EHR)
Sex IV EHR
Smoker IV EHR
Indigenous IV EHR
Diagnoses IV EHR
Medication list number IV EHR
Prescriptions previous 12 months IV EHR
Prescriptions ordered during the trial DV EHR
Pathology received previous 12 months IV EHR
Pathology received during the trial DV EHR
Imaging received previous 12 months IV EHR
Imaging received during the trial DV EHR
Chief diagnoses IV EHR
Time from hospital discharge to appointment IV EHR
Time from request for same day appointment
(< 16 yo) to being seen
IV EHR
Consultation number IV EHR
Consultation time length IV EHR
Hospitalisations previous 12 months (ED + admission) IV EHR
Hospitalisation during the trial (ED + admission) DV EHR
Mortality during the trial DV EHR
Hospitalisation previous 12months (ED + admission) IV State hospital data
Hospitalisation during the trial and 5 years following
(ED + admission)
DV State hospital data
Prescriptions filled previous 12months IV PBS
Prescriptions filled during the trial and 5 years following DV PBS
Pathology billed previous 12months IV MBS
Pathology billed during the trial and 5 years following DV MBS
Imaging billed previous 12months IV MBS
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Table 3 EQuIP-GP data variables (Continued)
Data level Variable Dependent (DV) or
independent variable (IV)
Source
Imaging billed during the trial and 5 years following DV MBS
Specialist consultations previous 12 months IV MBS
Other specialist consultations during the trial and 5 years following DV MBS
Mortality during the trial and 5 years following DV Deaths registry
aCanadian Institute for Health Information (CIHI). Measuring Organizational Attributes of Primary Health Care Survey. Available at: https://www.cihi.ca/sites/default/
files/info_phc_organize_en.pdf [Accessed 8 January 2019]
bCanadian Institute for Health Information (CIHI). Attributes of Primary Health Care: Provider Survey. Available at: https://www.cihi.ca/sites/default/files/document/
info_phc_provider_en.pdf [Accessed 8 January 2019]
C5-level EQ-5D version (EQ-5D-5 L). Available at: https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/ [Accessed 8 January 2019]
Fig. 3 EQuIP-GP program logic
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maximum variation approach to sampling of patients
(age, gender, comorbidities) will be applied to invita-
tion for the qualitative interviews.
Data management
On receipt of their consent forms, all participants (prac-
tice and patient) will be assigned a code, which will link
their data to a master-sheet which will contain partici-
pants’ demographic details and location. The master-
sheet will be kept secure and confidential by the project
coordinator in a password-protected file in the project
data management system. All data for the evaluation of
the project will be identified by the participants’ code
only. This is so that the data can be kept confidential,
but can be re-identified to enable appropriate grouping
and analysis in the case studies at the end of the study.
As general practices will be involved in the extraction of
their own consultation time and access data, data extrac-
tion will be performed by a staff member of the practice
who has usual access to the data.
All participants (practices and patients) will have the
choice of providing their data in hard copy or online
data collection forms. We will use ‘CloudStor’ as a se-
cure, password-protected, cloud-based data collection
and storage facility for participant-provided project re-
search data [38]. The CloudStor server for the project is
located in Australia. Permission for access to the data
within the research team will be an only-if-needed basis.
Hard copies of all consent forms will be stored in locked
filing cabinets in the Departments of General Practice at
each respective university (or password-protected folder
on CloudStor if in soft copy form).
After data integrity checks, data extracts received from
MedicineInsight will be stored in CloudStor. Data col-
lected from the MBS, PBS, hospitalisation and deaths
registries will be collected for 5 years following the trial,
but only with express consent from the participants.
These data will be stored and analysed in the Secure
Unified Research Environment (SURE) maintained by
the SAX Institute [39]. SURE is a purpose-built remote-
access data research laboratory and storage facility with
servers located in Australia.
Interview and IF diary data will be stored securely at
each site during the collection period.
De-identification will take place after transcription of
interviews. The code sheets and de-identified transcripts
will be stored separately in CloudStor.
Quantitative data analysis
Baseline characteristics will be summarised at the collab-
orating PBRN centre and general practice levels within
each trial arm, to provide counts and frequencies for cat-
egorical variables and means with standard deviations or
medians and ranges for continuous variables, as
appropriate. The primary outcome measure is a be-
tween-group difference in changes in the domain of
relational continuity, as measured in the appropriate
scale of the PCAT [34] at completion of the trial in
comparison with baseline. Between-group differences
in the domains of accessibility, coordination and com-
prehensive care in participants will also be measured
and tested using the relevant domain scales of the
PCAT [34]. To account for the potential effects of
clustering, we will use hierarchical linear models with
random main effects specified at the general practice
level. Total prescription counts for the 12 months
prior to trial commencement will also be used to
control for case-mix across the trial.
Similarly, each of the other specified outcome vari-
ables (Table 2) will be statistically analysed using
multi-level modelling methods to test for between-
group (intervention vs. control) differences in the
change in variables over the course of the study
period. It is intended that data collection from admin-
istrative datasets (MBS, PBS and hospital admissions)
will be continued beyond the trial period for 5 years,
and analysed similarly. Data will not be excluded on
the basis of non-adherence or protocol violation. The
mixed models treat the data as missing at random
and incorporate partial datasets, and are appropriate
for analysis of datasets with missing data.
Qualitative data analysis
Using a realist evaluation approach to analysis, we will it-
eratively generate context-mechanism-outcome configura-
tions (CMOc) to clarify what works for whom, why, when
and in what context at the individual and practice level
[29]. A framework analysis approach will allow us to iden-
tify relationships and patterns across diverse data sources,
including transcripts, documents, diary entries and obser-
vations. Framework analysis has been widely used in
health research [40, 41]. Importantly, when using nested
case studies as we are, framework analysis facilitates an or-
dered and organised way to compare and contrast data
both across multiple cases and within individual cases.
We will use the seven-step process proposed by Gale
et al. [42] to undertake the framework analysis. These
steps are 1) transcription; 2) familiarisation; 3) coding; 4)
developing a working analytical framework; 5) applying
the framework; 6) charting the data; and 7) interpreting
the data. By taking this approach we will be able to de-
velop clusters of themes that facilitate both explanatory
and descriptive conclusions directly relevant to our case
study approach. Case study analysis calls for early ana-
lysis and organisation of data, and coding is one way to
do this. We will utilise NVivo for Teams for coding and
management of the qualitative data sets [43].
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Health economic evaluation
The payment model has been designed following the net
benefit correspondence theorem (NBCT) [17–19, 44] to
create continuous quality of care improvement incen-
tives with a conservatively health system budget neutral
mechanism; with quality of care incentive payments rela-
tive to expected downstream cost savings from improved
quality. The NBCT provides a generalised method to en-
able appropriate incentives for improving health system
performance, which, as in hospital applications [17, 19],
has robust coverage and comparability conditions to cre-
ate appropriate accountability and prevent perverse in-
centives - cost and effect shifting and cream skimming.
Importantly, as quality improvement incentives are
conservatively budget neutral or potentially somewhat
cost saving to the health system, if the trial finds they
are effective in improving quality of care relative to usual
care, the mechanisms design provides for strong policy-
relevant integration into current practice in a health sys-
tem budget-constrained environment.
Generalisability, implementation and scalability of any
such trial findings from case control analysis will be
aided by triangulation with qualitative research and pre-
post analysis of impacts in the intervention arm, with
particular consideration of barriers and enablers to study
findings.
The health economic analysis of trial outcomes will
jointly consider the health effects and net costs, includ-
ing downstream health system (prescribed medication
and hospital) costs of a capitation-based GP payment
system, where bonus payments are continuous across
specified ranges for quality of care measures for each of
the activities proposed [17–19, 45].
Analysis with patient level data will include representing
joint cost and effect distributions on the cost-effectiveness
plane (two strategy comparisons), cost-disutility plane
(multiple strategy comparisons) and relevant summary
measures. These summary measures include internation-
ally recognised best practice measures of the level of the
probability of, and expected gain from, being cost-effect-
ive: net benefit and cost-effectiveness acceptability curves
for two strategy comparison [46]; expected net loss curves
and frontiers for multiple strategy comparisons [17, 18,
45], and expected net loss planes and surfaces with mul-
tiple domain of effect comparisons [17, 44].
Sample size and power
To reduce bias and cross-group contamination, we
propose to recruit 36 practices and then randomise
practices to intervention and control groups of equal
sizes. A total of 1800 patients (50 patients per practice)
will then be recruited according to identical inclusion
and exclusion criteria. The sample size will allow us to
detect a change of 0.2 in the mean score of PCAT
relational continuity scale (out of a total maximum of
4.0) with 98% power for adult participants, assuming an
intracluster correlation coefficient (ICC) of 0.05 at the
practice level. The study is powered to detect a similar
change in the other domains of the PCAT [47].
In addition, the trial is powered to detect a 40% reduc-
tion in PAHs in the 5 years following the trial in com-
parison with the 12months prior to the trial in an adult
high-risk population with 80% power, assuming an an-
nual PAH rate of 7.5%, ICC of 0.02, attrition of four
practices and 25% attrition of patients from remaining
practices. Due to funding and time constraints, it is not
possible to adequately power the trial to measure a re-
duction in PAHs within the study period. Therefore, the
study investigators will establish data collection proce-
dures to enable ongoing data collection and analysis for
up to 5 years.
Trial governance
All Chief Investigators are members of the trial steering
committee, which meets every 2 weeks. Its remit in-
cludes data management. It is independent from the
sponsor. Any reports of potential harm from participat-
ing general practices or patients will be investigated by
the Steering committee and, if appropriate, reported to
the ethics committees.
Discussion
This trial consists of a practice-based intervention imple-
mented in the primary care setting and predominantly
using quantitative data collection and analysis. The trial
is designed to test the effects of a new funding model
that provides financial incentives for continuous quality
improvement in general practice, proportional to the ex-
pected downstream cost savings. As part of the trial de-
sign, nested case studies are planned. These are intended
to contextualise the quantitative findings and provide in-
sights into the attitudes and beliefs of patients and prac-
titioners, and their perceptions about the success or
otherwise of the intervention.
The development of the intervention was underpinned
by several key tenets, namely that:
 high-quality primary health care can reduce the use
of secondary care, thus reducing health system
costs;
 the design and use of financial models that support
high-quality primary care are crucial to the uptake
of quality improvement activities and better patient
outcomes; and
 financial incentives for quality improvement are
more likely to succeed when incentives are
continuous and targeted to specific tasks that are
closely linked to high-quality care.
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Thus, the trial was designed to incentivise GPs to pro-
vide enrolled patients with longer consultations, same
day access and rapid follow-up after hospitalisation, and
to achieve associated quality improvements linked to
these tasks. The primary outcome measure of the trial is
patient-perceived relational continuity and secondary
outcomes include changes in pathology and imaging,
total prescriptions and rates of PAHs - all indicators of
quality of care.
The design of funding models to support high-qual-
ity primary care is crucial to the uptake of quality
improvement activities and better patient outcomes
[48]. Health economic theory suggests that incentives
with GP payments based on fee-for-service can be
significantly improved with capitation payments con-
ditional on continual quality improvement [49–54].
Indeed, our review of international financial models
for effective primary care indicated that a blend of
fee-for-service, capitation and pay-for-performance el-
ements appeared to provide the best balance between
improved patient outcomes and productivity. How-
ever, the evidence strongly suggested that the incen-
tives were only successful when targeting tasks
closely linked to professional standards of high-qual-
ity care [48].
The funding model within the trial seeks to provide in-
centives to encourage:
 access to a preferred provider, longer
consultations and structured follow-up after
hospitalisation among older and chronically ill
general practice patients;
 reduced referrals for specified radiology and
pathology services, and overall medicine
prescriptions for older and chronically ill general
practice patients;
 improved access to same-day care for under
16-year-olds with defined comorbidities; and
 reduced PAHs and emergency department
attendances for all enrolled patients.
It is important to note that the absolute incidence
of PAHs in the general population is low at around
2.8% per annum, which means that enrolling a non-
selected cohort of patients is likely to lead to a null
trial with time and funds available. In the 65–74 years
age group, the national rate of PAH for 20011/12 was
7,344.8 per 100,000 population (7.3%). For those aged
75 years and over, the rate was 13.4% [55].
Chronic conditions contribute a significant proportion
of PAHs, with diabetes complications, COPD, cardiac
failure, asthma and angina being most common [56].
Hence, we have focused on high-risk chronic/complex
patients aged 18–65 years with the highest-risk ACSCs
(COPD, diabetes, angina, ischaemic heart disease, car-
diac failure, asthma) expected to have greatest benefit
and health system cost saving where the model of care is
effective.
The rate of PAHs in the general population under
16 years of age is approximately 2% per annum [55].
Hence, we have targeted recruitment of patients aged
less than 16 years to those with an increased risk of
hospitalisation. Research from New Zealand has dem-
onstrated a high rate of re-hospitalisation in under
15-year-olds with a defined expert-derived list of
child-specific potentially avoidable hospitalisations
(approximately 80% of re-hospitalisations up until 15
years of age) [57]. We are therefore using these diag-
noses to recruit participants (includes asthma, epi-
lepsy, acute bronchiolitis, pneumonia, croup and
dental conditions).
We are using an embedded mixed methods design
to incorporate a qualitative component into an out-
comes-based randomised controlled trial. This qualita-
tive data will be used to develop understanding of
how the intervention is experienced by participants,
and to help contextualise and explain the quantitative
results. Our analysis aligns with Creswell and Plano
Clark’s model of mixing data using embedded mixed
method design [58]. At a pragmatic level, we antici-
pate that by integrating the embedded qualitative
component with our quantitative trial data we will
better be able to:
 reveal and contextualise relationships between
variables and outcomes;
 explore and possibly explain differences in effect
size;
 assess the acceptability of the trial model from
multiple perspectives; and
 provide insight into discrete, potentially
unanticipated impacts of the model on patients and
practitioners.
The trial is designed to generate robust, policy-rele-
vant evidence of the impact of a new service model
of primary care practice, comprising targeted practice
incentives for patient enrolment with a preferred pro-
vider, longer consultations, same day access and
structured follow-up after hospitalisation, on the qual-
ity of primary care and health service utilisation for
patients at increased risk of hospitalisation. In
addition, the trial will provide evidence on continuous
quality improvement incentives which can be com-
pared to block funded pay-for-performance models in
the UK [59], the patient-centred medical home model
in the United States [60] and the Australian Govern-
ment ‘Health Care Homes’ trial [31].
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Trial status
The trial is ongoing, with patient recruitment commen-
cing June 1 2018 and completed December 31 2018 and
trial completion July 31 2019. The study was in in the
intervention and data collection stages at the time of the
protocol manuscript submission.
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